Huge Impact of COVID19 on Monoclonal Antibodies Market
Growing prevalence of chronic diseases across the globe is the major factor that propelling the growth of the market during the forecast period. Chronic diseases are diseases which continue for long time, and which generally cannot be prevented through vaccines or medications. The major reason for increasing chronic disease includes lack of nutritious diet, physical activities and aging population. The foremost chronic diseases include CVD, strokes, heart attack, cancer, diabetes, breast cancer, obesity, and other health disorders. Early detection is a major factor in managing chronic diseases. There is significant rise in number of patients with chronic diseases.
According to AllTheResearch,”The global monoclonal antibodies market was valued at USD 95.5 billion in 2018 and is expected to reach USD 150.8 billion in 2026, growing at a CAGR of 5.8% during the forecast period.
By Type
• In-vitro
• In-vivo
By Indication
• Cancer
• Inflammatory Diseases
• Autoimmune Diseases
• Infectious Diseases
• Microbial Diseases
• Others
By End-User
• Hospitals
• Research Institutes
• Others
According to America Cancer Society for 2017, several 1.6 million new cancer cases were diagnosed and 600,920 people dies due to cancer in the US. Additionally, NIH has estimated that there will be 1,735,350 new cases of cancer in the US by the end of 2018. The genetic alterations enable in driving development & progress of different types of cancer which are identified through platform of research studies. Genomic studies and advanced technologies enable defining driver mutation and alteration of DNA & RNA in many cancers. The genomic information from tumors and normal tissue are compared which helps the required genomic changes. The genomic methods are used to detect molecular characteristics for clinical pheno types which enables the detection of genetic changes. Therefore, the increasing genomic research further provide ample opportunity to the market.
The emerging economies such as Asia-Pacific region is one of the potential markets for monoclonal antibodies. The factors that will be favorable for the growth of the market in this region includes increasing government expenditures on healthcare in the region, and the presence of huge population suffering with various chronic diseases such as cancer, hypertrophic cardiomyopathies, arrhythmias and others. The average annual increase in government healthcare spending in the US is 4.5% and less than 1.5% in the European Union.
Get more Info @ https://www.alltheresearch.com/report/230/monoclonal-antibodies
About AlltheResearch:
AllTheResearch was formed with the aim of making market research a significant tool for managing breakthroughs in the industry. As a leading market research provider, the firm empowers its global clients with business-critical research solutions. The outcome of our study of numerous companies that rely on market research and consulting data for their decision-making made us realize, that it’s not just sheer data-points, but the right analysis that creates a difference.